Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Results of the M19-130 (SLEek) Phase 2 trial of upadacitinib given alone or as a combination therapy (ABBV-599) met the primary endpoint of systemic lupus erythematosus (SLE) Responder Index (SRI-4) and steroid dose less than or equal to 10 mg prednisone equivalent once per day at week 24 in patients with moderately to severely active SLE 1 , 2 No new safety signals were identified with upadacitinib, and a similar safety profile was observed for the combination therapy (ABBV-599) as for treatment with upadacitinib alone2, 3 , 4 , 5 , 6 , 7 SLE is a complex autoimmune disorder in which the body's immune system attacks healthy tissue of the musculoskeletal system, skin, kidneys, lungs and other critical organs, leading to symptoms such as fatigue, joint pain and impaired function. 8 , 9 NORTH CHICAGO, Ill.

AbbVie Advances Upadacitinib (RINVOQ®) to Phase 3 Clinical Trials in Systemic Lupus Erythematosus

A significantly higher proportion of patients with moderately to severely active ulcerative colitis treated with risankizumab achieved the primary endpoint of clinical remissiona (per Adapted Mayo Score) compared to placebo at week 12 in the Phase 3 INSPIRE induction study All secondary endpoints, including clinical, endoscopic and histologic outcomes, were met Safety results in this study were consistent with the known safety profile of risankizumab, with no new safety risks observed 1 Building on AbbVie's growing gastroenterology portfolio, risankizumab is an IL-23 inhibitor being evaluated as a treatment for adults with moderate to severe ulcerative colitis and approved for Crohn's disease, psoriatic arthritis, and psoriasis1 NORTH CHICAGO, Ill. , March 23, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive top-line results from INSPIRE, a Phase 3 induction study, showing risankizumab (SKYRIZI®,1200 mg intravenous [IV], at weeks 0, 4 and 8) met the primary endpoint of clinical remission (per Adapted Mayo Score) at week 12, as well as all secondary endpoints in adult patients with moderately to severely active ulcerative colitis.1 In the study, 20.3% of patients receiving risankizumab achieved clinical remission compared to 6.2% of patients receiving placebo (p

Risankizumab (SKYRIZI®) Achieves Primary and All Secondary Endpoints in Phase 3 Induction Study in Patients With Ulcerative Colitis

AbbVie's top-selling drug is facing competition -- and lower revenue. The company still has much to offer long-term investors.

2 Reasons to Buy AbbVie, and 1 Reason to Sell

Kimberly-Clark

Stanley Black & Decker

Backed by the U.S. government, the closely watched 10-year Treasury note offers a high degree of safety that stocks and other investments can't match. What they no longer offer, however, is a 4% annualized interest rate.

These 3 Dividend Growers Yield More Than the 10-Year Note

NORTH CHICAGO, Ill. , March 22, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for ABBV-951 (foscarbidopa/foslevodopa) for the treatment of motor fluctuations in adults with advanced Parkinson's disease.

AbbVie Provides Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa) New Drug Application

Johnson & Johnson

Even if we look at a longer time frame, AbbVie fares better, with its sales rising at an average annual growth rate of 21% to $58 billion in 2022, compared to $33 billion in 2019, while J&J's saw its revenue rise at an average annual rate of just 5% to $95 billion in 2022, compared to $82 billion

Should You Buy The Botox Maker Over Johnson & Johnson Stock?

Air Products and Chemicals

Algonquin Power & Utilities

Brookfield Renewable Partners

Cisco Systems

General Mills

Home Depot

Nutrien

Procter & Gamble

TC Energy

This month was a fantastic month for dividend raises, adding a solid $101.39 to our forward income. While our dividend income is down, the overall passive income continues to increase.

February 2023 Passive Income - Good Times

NVIDIA

AbbVie's business is trading at a discount, and that's a mistake investors should pounce on. Nvidia's stock should continue to rally as PC sales strengthen and companies get back to upgrading IT.

2 Growth Stocks to Buy Before the Bull Market Arrives

ATLANTA--(BUSINESS WIRE)---- $ABBV #AD--Alzamend Neuro Reports Third Quarter Fiscal 2023 Financial Results & Provides a Business Update; Company had $7.

Alzamend Neuro Reports Third Fiscal Quarter Financial Results and Provides a Business Update

Accenture Plc

Automatic Data Processing

Applied Materials

ASML Hld

Best Buy

Blackrock Inc

Expeditors International of Washington

Fastenal

Ferguson Enterprises Inc

Garmin

Infosys

KLA-Tencor

Lockheed Martin

Lowe's

Lam Research

Mastercard

Monolithic Power Systems

Merck

Paychex

Rollins

Snap-on

Skyworks Solutions

The 4-factor dividend growth portfolio was launched on November 1st, 2022, and is performing quite well. The portfolio lost by 34 bps to the S&P 500 Total Return during the month of February.

4 Factor Dividend Growth Portfolio - First Insight

AbbVie Inc. (NYSE:ABBV ) Barclays Global Healthcare Conference Call March 15, 2023 1:35 PM ET Company Participants Robert Michael - Vice Chairman & President Scott Reents - Senior Vice President & Chief Financial Officer Jeff Stewart - Executive Vice President & Chief Commercial Officer Roopal Thakkar - Development & Regulatory Affairs Conference Call Participants Carter Gould - Barclays Carter Gould Hi, good afternoon. Welcome to the Day 2 of the Barclays Global Healthcare Conference.

AbbVie Inc. (ABBV) Barclays Global Healthcare Conference (Transcript)

Scotts Miracle-Gro

Here Are A Few Marijuana Stocks For Your Portfolio The post Marijuana Stocks For Your March 2023 Watchlist appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™.

Marijuana Stocks For Your March 2023 Watchlist

Coca-Cola

Microsoft

All 5 of these stocks prioritize returning money to shareholders. These companies have each paid growing dividends between 10 years and 60 years.

5 Forever Dividend Stocks To Build A Portfolio Around

"Under My Skin: Untold Stories of Life with Eczema," uncovers the extraordinary physical and emotional impact of those living with the chronic skin disease, showing viewers the power of having the courage to seek help  U.S. audiences can stream the film on The Roku Channel starting April 1 NORTH CHICAGO, Ill. , March 15, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the launch of a new documentary film, "Under My Skin: Untold Stories of Life with Eczema,"  which debuted at South by Southwest® 2023 in Austin, Texas.

AbbVie Partners with Award-Winning Redglass Pictures on New Film Shedding Light on the Hidden Struggles of Those Living with Eczema

AbbVie is one of the most prominent biotechnology/healthcare stocks known for paying a good dividend. Besides the dividend, AbbVie didn't generate any returns on a one-year basis and is still a bit away from its all-time high.

AbbVie: Comparing The Current Valuation To Its Last Growth Cycle

Abbott Labs

Becton, Dickinson and Co.

Cardinal Health

Medtronic

Roper Technologies

West Pharmaceutical Services

While it is not the only factor to consider, the annual dividend can solidify whether a stock will benefit you financially. And among the many industry sectors to invest in, healthcare can be one of the most stable, especially regarding the dividend yield.

Healthcare Stocks With at Least 30 Years of Dividend Increases

AbbVie is down about 8% YTD and appears undervalued at 13 times earnings. Dividend coverage looks strong based on both Free Cash Flow and Earnings Per Share.

AbbVie: A 4% SWAN Stock

AbbVie's Humira sales may hold up better against biosimilars in the USA than they have in Europe. The pharmaceutical giant has a diverse portfolio of blockbuster drugs that should help to offset declining revenues in its leading therapies.

Weather The Fed With AbbVie's Strong Portfolio And Solid Dividend Growth

Apple

Caterpillar

Colgate-Palmolive

Clorox

General Dynamics

Hormel Foods

Starbucks

AT&T

AT&T 5.35 % Notes 2017-01.11.66 Global

Verizon

The system is clearly broken and has been for a while; however, I could find comfort in one thing, my dividends. These days, there are no shortages of accidental high yielding stocks but look at real cash on hand when viewing balance sheets.

DivHut Portfolio Update: February 2023

News for AbbVie Stock (ABBV)